April 2026 in “Journal of Pharmaceutical Innovation” In this study, the researchers developed and optimized a curcumin nanocrystal gel to enhance skin permeability, reporting improved dissolution properties and antiproliferative effects on cell lines, suggesting it as a promising topical delivery system.
March 2026 in “International Journal of Dermatology” In this study, two cases of generalized hypertrichosis in young children were reported as resulting from indirect exposure to topical minoxidil through skin contact with caregivers, emphasizing the importance of preventing unintended contact and recognizing potential reversible side effects in pediatric populations.
December 2025 in “Saudi Journal of Medicine and Public Health” This narrative review highlights the critical role of pharmacists in optimizing topical corticosteroid therapy through proper agent selection, dosing, and patient education to manage various steroid-responsive skin conditions effectively.
July 2024 in “Journal of Controlled Release” In this study, researchers developed topical tofacitinib-loaded cationic lipid nanoparticles, which improved absorption and targeted hair follicles in an ex vivo pig ear model, showing promise in treating alopecia areata by reducing symptoms through the JAK/STAT pathway.
In this study, researchers developed a novel gel formulation combining zinc oxide nanoparticles and finasteride-loaded nanostructured lipid carriers, which showed promising results for topical delivery and effective skin penetration, potentially offering a new treatment approach for androgenic alopecia.
May 1987 in “Inpharma (Balgowlah)” Topical minoxidil may slow hair loss but often doesn't lead to satisfactory hair regrowth and requires ongoing treatment.
July 2022 in “Journal of Investigative Dermatology” This study found that a new alcohol-free minoxidil hydrogel formulation showed comparable in vitro efficacy and skin absorption to the commercial minoxidil product for treating androgenetic alopecia.
4 citations
,
January 2009 in “International journal of trichology” Minoxidil topical foam is a better, less irritating treatment for hair loss.
42 citations
,
January 2007 in “Pediatric dermatology” This report describes an 11-year-old boy with Netherton syndrome who developed Cushing syndrome after using low-potency hydrocortisone ointment extensively, highlighting caution with long-term topical treatments in such conditions.
39 citations
,
April 2010 in “International Journal of Pharmaceutics” This study found that using monoolein cubic phase nanoparticles with an entrapped hydroxypropyl β-cyclodextrin/minoxidil complex increased minoxidil skin permeation, but minoxidil retention in the skin was higher with a traditional solution.
20 citations
,
January 2018 in “Expert opinion on emerging drugs” This review discusses the potential of Janus Kinase inhibitors for treating alopecia areata and other forms of alopecia, highlighting the need for further research on their long-term safety and optimal formulation.
17 citations
,
October 2013 in “F1000Research” This case report details a 2-year-old boy who developed generalized hypertrichosis after using 5% minoxidil foam for alopecia areata, highlighting the importance of caution and proper administration instructions for young children.
4 citations
,
March 2013 in “InTech eBooks” Confocal Laser Scanning Microscopy (CLSM) is a useful tool for studying how drugs interact with skin and diagnosing skin disorders, despite some limitations.
1 citations
,
July 2005 in “Drugs and the pharmaceutical sciences” Targeting drugs to hair follicles can treat skin conditions, but reaching deep follicle areas is hard and needs more research.
September 2020 in “Farmacja Polska” This review discusses various applications of foam systems in drug form technology, highlighting their potential to enhance drug solubility and release modifications, but reports no new clinical results.
This study found that topical finasteride was absorbed into the bloodstream to a minimal extent in male rats, even with repeated applications, suggesting low systemic exposure.
October 2015 in “Elsevier eBooks” Minoxidil is effective for hair growth and safe for long-term use.
May 2011 in “Journal of The American Academy of Dermatology” This research letter observed that patients with severe atopic dermatitis showed normal serum cortisol levels after hospitalization despite continued use of potent topical corticosteroids, though poor adherence may lead to overestimations of actual medication use.
Topical corticosteroids are effective for skin conditions but can have side effects.
4 citations
,
February 2021 in “Journal of Pharmaceutical Sciences” This study suggests that the developed PBPK model effectively predicts pharmacokinetic and pharmacodynamic profiles of topical finasteride and minoxidil on the scalp, indicating potential broader applicability for other formulations.
This study found that radiofrequency microneedling significantly enhanced the absorption of topical triamcinolone acetonide, with insertion depth being more influential than RF energy levels.
18 citations
,
October 2005 in “International Journal of Pharmaceutics” This study found that incorporating 0.5% TPGS into topical minoxidil solutions enhanced hair growth in mice, although increasing TPGS to 2% decreased effectiveness.
7 citations
,
January 2015 in “International Journal of Trichology” This case report describes a woman who experienced frontal edema after topical minoxidil application following mesotherapy, noting that excessive absorption of minoxidil may cause localized vasodilatory side effects.
12 citations
,
July 2020 in “Dermatologic Therapy” This review discusses the use of topical and oral minoxidil for pediatric hair disorders, pointing out the lack of guidelines and the potential risks associated with systemic absorption, but reports no clinical results.
5 citations
,
July 2003 in “Drug Development Research” In this study, using a novel topical androgen receptor suppressor, fluridil, significantly increased the percentage of growing hairs in males with androgenetic alopecia without systemic absorption or adverse side effects.
June 2026 in “Skin Appendage Disorders” This source reviews the use of topical tretinoin with minoxidil for androgenetic alopecia, indicating that while combined use may convert some minoxidil nonresponders to responders, clinical evidence is limited and increased absorption may lead to irritation concerns.
This study focused on developing a nanoemulsion-based gel for delivering minoxidil, aiming to enhance its contact time with the scalp and potentially improve skin absorption compared to conventional topical solutions.
17 citations
,
August 2002 in “Dermatologic Surgery” This study found that topical fluridil increased the anagen hair percentage in men with androgenetic alopecia without causing irritation or systemic absorption over 9 months.
March 2004 in “Journal of The American Academy of Dermatology” This study found that the vehicle of hydrocortisone impacts its absorption and therapeutic effectiveness, as demonstrated by efficacy tests using UV-erythema and vasoconstriction models.
January 2025 in “Case Reports in Gastrointestinal Medicine” This case report presented by the authors provides the first evidence of severe liver failure associated with the use of topical minoxidil, emphasizing the potential for hepatotoxicity even from drugs with minimal systemic absorption.